Background: Although recent experimental data strongly suggest that platinum-based chemotherapy (PBCT) could improve the outcome of triple-negative breast cancer (TNBC), clinical data are lacking. Here, the authors reviewed clinical outcome in patients with metastatic TNBC treated with PBCT.
Breast cancer is a worldwide health issue, as it represents the leading cause of cancer in women and the second leading cause of cancer-related mortality in women [1] , with an increasing incidence [2] . Until recently, the most useful classification for breast cancer was based exclusively on hormone receptor (estrogen receptor: ER and progesterone receptor: PgR) status and HER2 status: all tumours belong to one of the four subgroups, and each one has a different treatment strategy [3, 4] . The so-called 'triplenegative' subgroup (TNBC), defined as ER2/PgR2/HER22, therefore remains the only subgroup without specific targeted agents. In total, 12-20% of breast cancers are TNBC [5] [6] [7] . In addition, TNBC appears to have an aggressive behaviour [6, 7] with frequent and early visceral metastatic spread [6] [7] [8] and consequently poorer outcome [6] [7] [8] [9] . On pathological examination [6] , TNBC show large tumour size, high rates of node invasion and poor differentiation. For these various reasons, new therapeutic approaches are warranted.
Breast cancer must be considered to be a heterogeneous group of very different diseases, with very different prognoses.
Recent findings have defined a new classification of breast cancer, based on similarities in gene expression patterns [10] [11] [12] . Using microarray analysis, several authors have proposed an innovative approach and have classified breast cancers into five subgroups of tumours: 'luminal A', 'luminal B', 'HER2-positive', 'normal breast-like' and 'basal-like' [10] [11] [12] . Consistent studies have shown that basal-like and HER2-positive are the two groups with the worst prognosis [10] . Up to 85% of TNBC correspond to 'basal-like breast cancer' (BLBC) [6, 13] , derived from myoepithelial cells of the breast epithelium [13] . In view of the high level of genomic instability of TNBC/BLBC [14] , probably due to a deficiency of DNA repair mechanisms [15] , the use of platinum and alkylating agents in these patients is currently under investigation by many authors [13, 16] . Recent findings reinforce the link between BLBC and BRCA1 deficiency [6, 17] and support this approach. Phase III clinical trials testing platinum drugs in TNBC patients are ongoing [13, 16] , but, to our knowledge, no published data are yet available on this. This article presents the results of the Institut Curie experience of platinum-based chemotherapy (PBCT) in metastatic TNBC. In this retrospective analysis, the files of 143 female patients, who received PBCT for metastatic breast cancer (MBC), were reviewed, and their outcome was then assessed according to TNBC status.
patients and methods patients
In this retrospective study, 146 patients treated by PBCT for MBC at Institut Curie, between April 2000 and January 2008, were identified from our database. ER, PgR and HER2 status were recorded and patients were divided into two groups: 'TNBC patients' and 'non-TNBC patients'.
assessment of TNBC status ER and PgR status were available for all patients included in the study; these data were provided by the Institut Curie Pathology Department. HER2 status was not available in three patients (1.4%), who were excluded from the analysis.
treatment
All patients received PBCT: 120 of the 143 patients (83.9%) received cisplatin (CDDP), 8 patients (5.6%) received carboplatin and 15 patients (10.5%) initially received CDDP, and were then switched to carboplatin due to serious CDDP-related adverse events (AE) during treatment (renal failure, peripheral neuropathy, hearing loss or persistent emesis).
Different CDDP administration protocols were used, depending on the other drugs delivered: 50 mg/m 2 /day on day 2 (d2-d3) when associated with ifosfamide (107 patients); 75 mg/m 2 on d1 when associated with gemcitabine (four patients), docetaxel (six patients) or cyclophosphamide (three patients). In all cases, CDDP infusion was repeated every 3 weeks, for a planned course of six cycles. Carboplatin was administered at the AUC five dose levels. Ifosfamide was administered at a dose of 1500 mg/m 2 /day from d1 to d3, every 3 weeks. Administration protocols of all PBCT employed are listed in Table 1 .
The main combination used was CDDP-ifosfamide: N = 101 (70.2%). The median number of CT cycles delivered was 4 (range: 1-9). Eleven patients received an intensive PBCT regimen, in which CDDP was given in combination with ifosfamide and vinorelbine (NAvelbine Platine Ifosfamide, NAPI) for three cycles, and then followed by high dose chemotherapy (HDCT) and autologous bone marrow transplantation. Tumour response was analysed after the three cycles of PBCT. As these patients were equally distributed between the two groups (five TNBC and six non-TNBC), they were maintained in the analysis.
response assessment and follow-up
Before each cycle, clinical examination including clinical tumour response and full blood tests were carried out. Radiological assessment of response by computed tomography scan was carried out before the first cycle of treatment, and after three and six cycles of CT. Objective responses (OR) to CT were evaluated using RECIST guidelines [18] ; complete response (CR), partial response (PR) and stable disease (SD) had to be maintained at 4 weeks after the first documentation of response. Additional radiological examinations were carried out if necessary, particularly chest X-ray before each cycle in the case of thoracic measurable disease.
The efficacy of PBCT in TNBC and non-TNBC patients was analysed according to overall survival (OS), progression-free survival (PFS) and OR. The PBCT safety profile was also assessed, with particular attention to CDDP-related side-effects. The final objective of this study was to establish prognostic factors for outcome in TNBC patients, if possible.
statistical considerations
Patient characteristics of the two groups (TNBC versus non-TNBC) were compared by a chi-square test for categorical data, or Student's t-test for quantitative or ordinal data. Response to treatment (CR/PR/SD/progressive disease (PD)) was compared by chi-square test. Survival curves were constructed by the Kaplan-Meier method and compared by means of the log-rank test. All P values were two sided. PFS and OS were measured from the date of initiation of PBCT until progression in any site or death from any cause (PFS) or until death from any cause (OS).
results

patients
A total of 143 cases were analysed, including 93 (65%) patients with TNBC and 50 (35%) patients with non-TNBC. Patients' characteristics are given in Table 2 . Median age was 48 years (range: 29-76) with no significant difference between groups.
Patients in the TNBC group had significantly more aggressive tumours at diagnosis: 79.6% of histological Easton-Ellis grade 3 versus 38% in the non-TNBC group (P < 0.001). No significant difference was observed between groups for tumour size [32.2% of TNM (tumour-node-metastasis) T3-T4 tumours in TNBC versus 30% in non-TNBC], or node invasion (64.5% in TNBC versus 60% in non-TNBC). Twenty-nine patients (19.9%) had metastatic disease at the time of the initial diagnosis. All patients had metastatic disease at the beginning of PBCT. A total of 110 patients (76.9%) had visceral sites, with similar rates in the two groups (74.2% in TNBC versus 82% in non-TNBC, P = NS), as rates of central nervous system and liver metastases.
Prior exposure rates were 72% to anthracyclines and 82.5% to taxanes, with no significant difference between the two groups. Most patients had received these drugs in the adjuvant setting; 96 patients (67.1%) had been exposed to both drugs.
Retrospectively, we identified 25 patients who were referred for BRCA1 or two mutations detection based on family history or age <36. BRCA mutations were identified in 11 patients: 8 BRCA1 and 3 BRCA2. All but one BRCA1 patient had TNBC (91%). 
PBCT administration
TNBC patients received PBCT in a metastatic setting significantly earlier than non-TNBC patients: the percentage of patients undergoing first-or second-line CT for MBC was 57% in TNBC versus 12% in non-TNBC (P < 0.001). Moreover, the median number of prior CT regimens was 1.65 in the TNBC group, 2.82 in the non-TNBC group (P < 0.001) and 2.06 for the overall cohort. The median number of CT cycles delivered was 4 for the overall cohort (range: 1-9), and 5 for TNBC versus 4 for non-TNBC.
response rate and survival Table 3 shows response to PBCT in the two groups. Median follow-up was 44 months. For the overall population (N = 143), median OS and median PFS were 11 and 5 months, respectively. Despite a trend in PR in favour of TNBC patients, no significant difference in OR was observed between the two groups: no patient achieved CR, and the PR rate was 33.3% in the TNBC group versus 22% for non-TNBC, P = 0.1. Excluding HER2-positive patients, the response rate, 18%, was the same for ER+ HER2 population (N = 33) (details in Table 4 ).
Response rate of BRCA-positive patients does not seem to response differently to the platinum regimes than those who were negative. Out of 11 identified BRCA-mutated patients, five had an objective response (45%), one a SD and five disease progression (Table 3) . No significant difference was observed for OS, PFS and response duration between TNBC and non-TNBC (see Figure 1 ). Median response duration was 8 months in the TNBC group versus 7 months in the non-TNBC group.
Comparing OS from first diagnosis of metastasis, we observed highly significant shorter survival duration for TNBC: median OS was 22 months in TNBC group versus 40 months in non-TNBC (P = 0.008) (Figure 2) .
Median OS and median PFS were improved in patients responding to CT: 27 versus 8 months (P < 0.001) and 10 versus 4 months (P < 0.001), respectively (see Figure 3) . As shown in Figure 4 , the other main prognostic factor identified for poorer OS was visceral metastasis sites (P < 0.001): median OS was 17 months in patients without visceral metastases versus 9 months for the other patients (P < 0.001).
adverse events
World Health Organisation (WHO) grade 3-4 AE are listed in Table 5 . In all, 104 patients (72.7%) experienced at least one grade 3-4 AE. Grade 3-4 AE occurred more often in TNBC patients, but the difference between the two groups was not significant: 72 in the TNBC group (77.4%) versus 32 in the other group (64%), P = 0.055. One patient died from sepsis during neutropenia and another one developed CDDP-related severe renal failure (grade 3). The most common grade 3-4 AE were haematological (HAE). Grade 3-4 neutropenia occurred in 82 patients (57.3%), and febrile neutropenia occurred in 14.7% of patients. Granulocyte colony-stimulating factor was not systematically recommended, but was only administered as secondary prevention (i.e. after one episode of grade 3-4 neutropenia or febrile neutropenia). Grade 3-4 thrombocytopaenia (46 patients, 32.2%) and grade 3-4 anaemia (40 patients, 28%) were also frequently observed. Red blood cell transfusion was carried out for serum haemoglobin levels <8.0 g/dl, and recombinant erythropoietin was administered according to WHO recommendations [19] . Platelet transfusion was carried out for platelet count <20 000/ml. No difference in grade 3-4 HAE was observed between the two groups.
As expected, other serious CDDP-related AE, reported when greater than grade 1, were peripheral neuropathy (grade 2 AE in 12 patients, 8.4%) and renal failure (grade 2 AE in 6 patients, 4.2%). Auditory damage occurred in 9.1% in all (13 patients), including tinnitus and hearing loss. In all cases of auditory damage, clinical symptoms resolved completely after discontinuation of CDDP. Non-haematological AE (NHAE) was observed equally in the two groups. One patient required CDDP discontinuation because of unacceptable emesis.
In 15 patients, CDDP was replaced by carboplatin during PBCT: 11 patients in the TNBC group and 4 patients in the non-TNBC group. The reasons for platinum switching were grade 2 hearing loss (10 cases), grade 2 renal failure (6) and grade 2 peripheral neuropathy (1).
discussion
Several studies on TNBC have provided data establishing that this subtype of breast cancer is associated with the poorest prognosis, in terms of both clinical (young age, both local and distant aggressive course, shortened survival) and pathological features (large size, high grade, poor differentiation) [6] [7] [8] [9] [20] [21] [22] . Rakha et al. [13] , Reis-Filho et al. [7] and Schneider et al. [6] recently reviewed TNBC/BLBC, and the currently treatment options. Few treatment options are available and no recommendations can be proposed at the present time, due to the absence of phase III data on the topic. The substantial overlap between TNBC and BLBC [6, 13] and the growing parallel between TNBC, BLBC and BRCA1-related breast cancer tend to highlight the value of platinum salts in this indication. It has been hypothesised that these tumours could have similarities, especially defects in DNA double-strand break repair. Based on this rationale, drugs inducing DNA single-or double-strand breaks (i.e. alkylating agents and original article Annals of Oncology platinum salts) have recently been proposed. Several phase II and III trials in TNBC/BLBC patients are ongoing [13] [14] [15] [16] [23] [24] [25] , including a UK phase III trial triple negative tumor (TNT) comparing first-line carboplatin versus docetaxel in metastatic TNBC patients (TNT trial http://clinicaltrials.gov/ cet2/show/NCT00532727). In our study, BRCA-mutated patients' outcome did not seem to differ from other with PBCT, but the small sample size (11 patients) hinders any further conclusion. Many authors have used PBCT (mainly in combination with gemcitabine) as salvage therapy in anthracycline/taxane-resistant MBC [26] [27] [28] [29] [30] , with OR rates of 26%-50%, and median OS of 8-13 months (for complete review, see Table 6 ). In contrast, few published studies have investigated PBCT in metastatic TNBC. The study by Sirohi et al. [30] retrospectively reviewed 328 patients treated by PBCT for MBC, in neoadjuvant (94 patients, including 17 TNBC), adjuvant (79/11) and metastatic (155/34) settings, and then analysed outcome according to TNBC status. Note that many different CT drugs were associated with platinum salts. In neoadjuvant patients, the CR rate was increased in the TNBC group (88% versus 51%, P = 0.0005), although overall response rate was similar in the two groups. In metastatic patients, there was a slight but significant gain in median PFS for TNBC patients (6 versus 4 months, P = 0.05), a non-significant trend to improvement of OR (41% for TNBC versus 31% for non-TNBC, P = 0.3) and similar OS in the two groups. The authors concluded that PBCT could slightly improve the poor prognosis of TNBC. In a randomised phase II study in 126 second-line metastatic TNBC patients, Bhattacharyya et al. [31] compared a metronomic regimen of cyclophosphamide and methotrexate 6 cisplatinum. Response rate in the no platinum arm was 30% and 62% in the platinum arm TTP and OS were 7 and 12 months versus 13 and 16 months respectively. In the recent work of Byrski et al. [32, 33] , in neoadjuvant setting a high rate of pathological CR was observed after treatment with CDDP in 10 (83%) of 12 patients BRCA1 mutation carriers treated with CDDP. In the study of Silver et al. [34] , single-agent CDDP induced only pathological CRs in 22% of 28 patients with TNBC. Decreased BRCA1 expression may identify subsets of TNBCs that are CDDP sensitive.
Ifosfamide was used in combination with CDDP/carboplatin, as this drug has been shown to be active in MBC [35] , has already been tested with CDDP in various types of cancer [36] , and in view of the potential role of alkylating agents in TNBC/BLBC. The Institut Curie TNBC population showed a high rate of histological grade 3 tumours and a trend towards younger age (although not significant). Moreover, a trend in favour of better OR was also observed for TNBC versus non-TNBC, and not associated with any gain in PFS or OS. The major caveat of this study is that it was based on retrospective analysis and patients were not randomised. However, this treatment was proposed only to patients with aggressive disease according to TN status, or rapid resistance to standard therapy in young patients. Nevertheless, the absence of significantly different outcome between TNBC and non-TNBC (despite the fact that TNBC is known to have a poorer prognosis) could underlie a potential benefit of PBCT. The poor prognosis of TNBC was highlighted in our patients by OS since first diagnosis of metastasis with a median of 22 months compared with 40 months in non-TNBC (P = 0.008). The hypothesis of an improvement by PBCT obviously needs to be confirmed by a prospective trial. Survival curves according to presence or absence of visceral metastasis with a highly significant difference is reported. However, we acknowledge that the numbers were small in the non-visceral metastasis group (24 TNBC and 9 non-TNBC).
Finally, the safety profile of PBCT in our patients appeared to be comparable to that reported in previous studies on PBCT in MBC [24] [25] [26] [27] [28] [29] : HAE were usually the most serious, with febrile neutropenia in 10% to 15% of patients, and grade 3-4 neutropenia (13% to 78%), thrombocytopaenia (37% to 49%) and anaemia (15% to 31%) similar to our findings. The main NHAE reported in the literature are peripheral neuropathy (especially when CDDP is associated with vinorelbine), renal failure and severe emesis. These overall high rates of grade 3/4 toxic effects are high for palliative treatment, particularly in a cohort whose overall prognosis is poor and therefore where quality of life considerations are important. Selection of patients with adequate good performance status appears essential before considering this kind of treatment.
In conclusion, PBCT showed a clinical activity in our TNBC patients, with acceptable safety. Apart from response rate, no difference in outcome was observed between TNBC and non-TNBC patients, despite the fact that TNBC is known to have a poorer overall prognosis. We hypothesise that PBCT could improve the spontaneous poor prognosis of metastatic TNBC. This needs to be substantiated by prospective randomised trials. Future studies of PBCT in metastatic TNBC should probably include PARP inhibitors, in view of the encouraging preliminary results obtained with this new class in TNBC [37, 38] and their theoretical synergistic action with that of platinum salts and alkylating agents. 
